Enveda Biosciences (Boulder, Colorado; AI-enabled natural product discovery platform) continues to draw attention through September 2026 for ENV-308, the first-in-class oral small-molecule mimetic of Lac-Phe (N-lactoyl-phenylalanine, an exercise-produced signaling molecule) whose Phase 1 safety and tolerability data was reported August 18, 2026. The Phase 1 trial in 88 healthy volunteers showed ENV-308 was well-tolerated with low GI side effects and reduced circulating leptin as a biomarker signal that the drug reaches metabolically-active concentrations in humans. In preclinical animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that roughly 1 in 8 U.S. adults have used a GLP-1 medication and most stop within a year for cost, side-effect, or plateau reasons. Phase 2 will test whether ENV-308 helps people maintain weight after stopping GLP-1s. Timeline: realistic earliest approval 2028-2029. ENV-308 joins bimagrumab (Eli Lilly, anti-activin receptor Phase 3), HM17321 (Hanmi-Genentech UCN2 analog, Phase 1), and ARO-INHBE (Arrowhead RNAi, Phase 1/2a) in the muscle-preservation pipeline.
Enveda Biosciences (Boulder, Colorado, AI-enabled natural product discovery platform) reported positive Phase 1 results August 18, 2026 for ENV-308, a first-of-its-kind oral small molecule engineered to mimic the therapeutic effects of Lac-Phe (a hormone released during intense exercise) for the treatment of post-GLP-1 weight regain and lean-mass loss. In the Phase 1 trial (n=88 healthy volunteers), ENV-308 was extremely well tolerated including on gastrointestinal safety, and reduced circulating leptin as an exploratory metabolic-engagement signal. In animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that 1 in 8 U.S. adults use GLP-1 medications and the majority who take them for weight loss stop within one year. Phase 2 will test whether ENV-308 can help people maintain weight after stopping GLP-1s. Not a peptide, but the exercise-mimetic pathway is one of the leading commercial answers to the muscle-preservation and post-discontinuation regain problems that constrain the current peptide obesity therapeutic class.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented updated Phase 1/2a data on ARO-INHBE (an RNA interference therapeutic targeting Activin E) and ARO-ALK7 (RNAi targeting ALK7 receptor) at EASL 2026. Standalone data: ARO-INHBE monotherapy achieved mean visceral fat reduction of -9.9% at week 16 after a single dose and -15.6% placebo-adjusted after two doses at week 24, with a single dose increasing lean muscle tissue by 3.6%; ARO-ALK7 monotherapy achieved -14.1% placebo-adjusted visceral fat reduction at week 8 after a single dose. Combination data: ARO-INHBE plus low-dose tirzepatide (5 mg) enhanced reductions in visceral adipose tissue and liver fat content versus tirzepatide alone in participants with obesity with or without type 2 diabetes. Mean maximum Activin E reduction reached 85.3% at the 400 mg dose with persistent effect beyond 3 months. Additional 2026 readouts expected. The data extend the case for RNAi as a non-peptide, quarterly-dosed obesity add-on capable of shifting body composition rather than just body weight.